Skip to content
Bending the Curve Trial by Trial
?

Back to Childhood acute lymphoblastic leukemia (ALL)

References: Childhood acute lymphoblastic leukemia (ALL)

104 sources cited on this page. Links open the primary source.

  1. Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238(23):787-93. PubMedDOI
    CiteLoading…
  2. BURCHENAL JH, MURPHY ML, ELLISON RR, SYKES MP, TAN TC, LEONE LA, et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood. 1953;8(11):965-99. PubMedDOI
    CiteLoading…
  3. Frei E 3rd, Freireich EJ, Gehan E, Pinkel D, Holland JF, Selawry O, et al. Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate. Blood. 1961;18(4):431-54. DOI
    CiteLoading…
  4. Frei E 3rd, Karon M, Levin RH, Freireich EJ, Taylor RJ, Hananian J, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood. 1965;26(5):642-56. PubMedDOI
    CiteLoading…
  5. Dolowy WC, Henson D, Cornet J, Sellin H. Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia. Cancer. 1966;19(12):1813-9. PubMedDOI
    CiteLoading…
  6. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RW. L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. JAMA. 1967;202(9):882-8. PubMedDOI
    CiteLoading…
  7. Oettgen HF, Old LJ, Boyse EA, Campbell HA, Philips FS, Clarkson BD, et al. Inhibition of leukemias in man by L-asparaginase. Cancer Res. 1967;27(12):2619-31. PubMed
    CiteLoading…
  8. George P, Hernandez K, Hustu O, Borella L, Holton C, Pinkel D. A study of "total therapy" of acute lymphocytic leukemia in children. J Pediatr. 1968;72(3):399-408. PubMedDOI
    CiteLoading…
  9. Evans AE, Gilbert ES, Zandstra R. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer. 1970;26(2):404-9. PubMedDOI
    CiteLoading…
  10. Aur RJ, Simone J, Hustu HO, Walters T, Borella L, Pratt C, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971;37(3):272-81. PubMedDOI
    CiteLoading…
  11. Pinkel D. Five-year follow-up of "total therapy" of childhood lymphocytic leukemia. JAMA. 1971;216(4):648-52. PubMedDOI
    CiteLoading…
  12. Pinkel D, Simone J, Hustu HO, Aur RJ. Nine years' experience with "total therapy" of childhood acute lymphocytic leukemia. Pediatrics. 1972;50(2):246-51. PubMedDOI
    CiteLoading…
  13. Simone J, Aur RJ, Hustu HO, Pinkel D. "Total therapy" studies of acute lymphocytic leukemia in children. Current results and prospects for cure. Cancer. 1972;30(6):1488-94. PubMedDOI
    CiteLoading…
  14. Elion GB. The purine path to chemotherapy. Science. 1989;244(4900):41-7. PubMedDOI
    CiteLoading…
  15. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24. PubMedDOI
    CiteLoading…
  16. Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339(9):591-8. PubMedDOI
    CiteLoading…
  17. Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, et al. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience. Cancer. 1998;82(7):1387-95. PubMedDOI
    CiteLoading…
  18. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-71. PubMedDOI
    CiteLoading…
  19. Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354(9172):34-9. PubMedDOI
    CiteLoading…
  20. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691-6. PubMed
    CiteLoading…
  21. European Medicines Agency. Glivec (imatinib): European public assessment report (EPAR) page. Marketing authorisation issued 07/11/2001; page last updated 12/11/2025. Page read 2026-10-20. Source
  22. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101(10):3809-17. PubMedDOI
    CiteLoading…
  23. US Food and Drug Administration. Approval letter, NDA 21-673, Clolar (clofarabine) intravenous infusion, Genzyme Corporation; accelerated approval, 28 December 2004. Source
  24. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23(15):3376-82. PubMedDOI
    CiteLoading…
  25. US Food and Drug Administration. Approval letter, Arranon (nelarabine) injection, NDA 21-877, GlaxoSmithKline. Electronic signature date 28 October 2005. Source
  26. Avramis VI, Tiwari PN. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006;1(3):241-54. PubMed
    CiteLoading…
  27. European Medicines Agency. Sprycel (dasatinib): European public assessment report (EPAR) page. Marketing authorisation issued 20/11/2006; page last updated 02/10/2026. Page read 2026-10-20. Source
  28. U.S. Food and Drug Administration. Approval letter, STN BL 103411/5052, pegaspargase (Oncaspar), supplement expanding the indication to first-line multi-agent treatment of acute lymphoblastic leukemia, 2006. Source
  29. Miller DR. A tribute to Sidney Farber-- the father of modern chemotherapy. Br J Haematol. 2006;134(1):20-6. PubMedDOI
    CiteLoading…
  30. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-64. PubMedDOI
    CiteLoading…
  31. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240-250. PubMedDOI
    CiteLoading…
  32. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-85. PubMedDOI
    CiteLoading…
  33. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515-23. PubMedDOI
    CiteLoading…
  34. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-80. PubMedDOI
    CiteLoading…
  35. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730-41. PubMedDOI
    CiteLoading…
  36. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-81. PubMedDOI
    CiteLoading…
  37. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755-61. PubMedDOI
    CiteLoading…
  38. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-14. PubMedDOI
    CiteLoading…
  39. Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376(9757):2009-17. PubMedDOI
    CiteLoading…
  40. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936-45. PubMedDOI
    CiteLoading…
  41. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-9. PubMedDOI
    CiteLoading…
  42. Spain PD, Kadan-Lottick N. Observations of unprecedented remissions following novel treatment for acute leukemia in children in 1948. J R Soc Med. 2012;105(4):177-81. PubMedDOI
    CiteLoading…
  43. US Food and Drug Administration. Supplement approval letter, Gleevec (imatinib mesylate) tablets, NDA 021588/S-037, Novartis Pharmaceuticals Corporation. Electronic signature date 25 January 2013. Source
  44. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518. PubMedDOI
    CiteLoading…
  45. Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185-96. PubMedDOI
    CiteLoading…
  46. Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199-209. PubMedDOI
    CiteLoading…
  47. Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123(1):70-7. PubMedDOI
    CiteLoading…
  48. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517. PubMedDOI
    CiteLoading…
  49. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005-15. PubMedDOI
    CiteLoading…
  50. Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014;28(7):1467-71. PubMedDOI
    CiteLoading…
  51. European Medicines Agency. Blincyto: EPAR page (conditional marketing authorisation 23 November 2015, standard authorisation 18 June 2018; page lists an update dated 22 September 2026). Accessed 20 October 2026. Source
  52. Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677-90. PubMedDOI
    CiteLoading…
  53. US Food and Drug Administration. BLA 125557/S-005 and S-006 supplement approval letter, Blincyto (blinatumomab), Amgen; 30 August 2016. Source
  54. Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380-8. PubMedDOI
    CiteLoading…
  55. von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016;34(36):4381-4389. PubMedDOI
    CiteLoading…
  56. European Medicines Agency. Besponsa: EPAR page (marketing authorisation issued 28 June 2017; page lists an update dated 18 May 2026). Accessed 20 October 2026. Source
  57. US Food and Drug Administration. BLA 125557/S-008 supplement approval (replacement letter), Blincyto (blinatumomab), Amgen; effective date 11 July 2017 (letter signed 12 July 2017). 2017. Source
  58. US Food and Drug Administration. BLA approval letter, STN 125646/0, tisagenlecleucel (Kymriah), Novartis Pharmaceuticals Corporation; 30 August 2017. Source
  59. US Food and Drug Administration, Center for Biologics Evaluation and Research. Summary Basis for Regulatory Action, KYMRIAH (tisagenlecleucel), STN 125646/0; 30 August 2017. Source
  60. Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H, et al. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017;129(25):3352-3361. PubMedDOI
    CiteLoading…
  61. European Medicines Agency. Kymriah: EPAR page (marketing authorisation issued 23 August 2018; page lists an update dated 1 September 2026). Accessed 20 October 2026. Source
  62. US Food and Drug Administration. BLA 125557/S-013 accelerated approval letter, Blincyto (blinatumomab), Amgen; 29 March 2018. Source
  63. US Food and Drug Administration. Supplement approval letter, Sprycel (dasatinib) tablets, NDA 021986/S-021, Bristol-Myers Squibb Company. Electronic signature date 21 December 2018. Source
  64. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439-448. PubMedDOI
    CiteLoading…
  65. Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018;36(22):2306-2314. PubMedDOI
    CiteLoading…
  66. US Food and Drug Administration. Supplement approval letter (fulfillment of postmarketing requirement), Arranon (nelarabine) injection, NDA 021877/S-010, Novartis Pharmaceuticals Corporation. Electronic signature date 31 July 2019. Source
  67. Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J Clin Oncol. 2019;37(35):3377-3391. PubMedDOI
    CiteLoading…
  68. Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019;37(25):2246-2256. PubMedDOI
    CiteLoading…
  69. Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(28):3282-3293. PubMedDOI
    CiteLoading…
  70. Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA Oncol. 2020;6(3):358-366. PubMedDOI
    CiteLoading…
  71. Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. J Clin Oncol. 2021;39(13):1437-1447. PubMedDOI
    CiteLoading…
  72. Brivio E, Locatelli F, Lopez-Yurda M, Malone A, Díaz-de-Heredia C, Bielorai B, et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood. 2021;137(12):1582-1590. PubMedDOI
    CiteLoading…
  73. Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):833-842. PubMedDOI
    CiteLoading…
  74. Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):843-854. PubMedDOI
    CiteLoading…
  75. Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study. J Clin Oncol. 2021;39(4):295-307. PubMedDOI
    CiteLoading…
  76. US Food and Drug Administration. Supplement approval letter (fulfillment of postmarketing requirement), Clolar (clofarabine) injection, NDA 021673/S-027, Genzyme Corporation; electronic signature date 18 July 2022. Source
  77. O'Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. J Clin Oncol. 2022;40(9):956-967. PubMedDOI
    CiteLoading…
  78. US Food and Drug Administration. BLA Multidisciplinary Review and Evaluation, BLA 125557 S-023 and S-026, Blincyto (blinatumomab), Reference ID 5193267; review completion date 20 June 2023. Source
  79. Hunger SP, Tran TH, Saha V, Devidas M, Valsecchi MG, Gastier-Foster JM, et al. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2023;10(7):e510-e520. PubMedDOI
    CiteLoading…
  80. Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2023;41(9):1664-1669. PubMedDOI
    CiteLoading…
  81. van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. N Engl J Med. 2023;388(17):1572-1581. PubMedDOI
    CiteLoading…
  82. US Food and Drug Administration. Besponsa (inotuzumab ozogamicin) prescribing information as approved with BLA 761040/S-003 (Reference ID 5341472); 6 March 2024. Source
  83. US Food and Drug Administration. FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia. Notice, 6 March 2024. Source
  84. US Food and Drug Administration. BLA 761040/S-003 supplement approval letter, Besponsa (inotuzumab ozogamicin), Wyeth Pharmaceuticals LLC; 6 March 2024. Source
  85. US Food and Drug Administration. BLA 125557/S-028 supplement approval letter (corrected letter), Blincyto (blinatumomab), Amgen Inc.; electronic signature date 14 June 2024. Source
  86. National Cancer Institute. Cancer in Children and Adolescents (fact sheet). Page updated 27 August 2024; accessed 20 October 2026. https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet Source
  87. Rabin KR, Devidas M, Chen Z, Ji L, Kairalla J, Hitzler JK, et al. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024;42(2):218-227. PubMedDOI
    CiteLoading…
  88. Kumar Upadhyay A, Prakash A, Kumar A, Jena S, Sinha N, Sharma S. Dr. Sidney Farber (1903-1973): Founder of Pediatric Pathology and the Father of Modern Chemotherapy. Cureus. 2024;16(8):e68286. PubMedDOI
    CiteLoading…
  89. Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025;392(9):875-891. PubMedDOI
    CiteLoading…
  90. Inaba H, Teachey D, Annesley C, Batra S, Beck J, Colace S, et al. Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(2):41-62. PubMedDOI
    CiteLoading…
  91. ClinicalTrials.gov. NCT00549848 (Total Therapy Study XVI). Registry record, accessed 20 October 2026. NCT00549848
  92. ClinicalTrials.gov. NCT03007147 (AALL1631). Registry record, accessed 20 October 2026. NCT03007147
  93. ClinicalTrials.gov. NCT03959085 (AALL1732). Registry record, accessed 20 October 2026. NCT03959085
  94. ClinicalTrials.gov. NCT04307576 (ALLTogether1). Registry record, accessed 20 October 2026. NCT04307576
  95. ClinicalTrials.gov. NCT05327894 (Interfant-21). Registry record, accessed 20 October 2026. NCT05327894
  96. ClinicalTrials.gov. NCT07476729 (IntReALL BCP 2020). Registry record, accessed 20 October 2026. NCT07476729
  97. DuVall AS, McNeer J, Cheung MC, Adrianzen-Herrera DA, Advani A, Aljurf M, et al. American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026;10(13):4671-4708. PubMedDOI
    CiteLoading…
  98. U.S. Food and Drug Administration, Oncology Center of Excellence. Pediatric Oncology Drug Approvals (table current as of February 2026; page content current as of 03/03/2026). Accessed 2026-10-20. Source
  99. US Food and Drug Administration. Verified Clinical Benefit | Cancer Accelerated Approvals. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Content current as of 16 October 2026. Source
  100. O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, et al. American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026;10(13):4726-4756. PubMedDOI
    CiteLoading…
  101. Schrappe M, Locatelli F, Valsecchi MG, Zugmaier G, Vossen-Gajcy M, Starý J, et al. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. N Engl J Med. 2026;395(11):1075-1089. PubMedDOI
    CiteLoading…
  102. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Leukemia - Acute Lymphocytic Leukemia (ALL). Page accessed 20 October 2026; the page displays no update date (its HTML metadata gives 22 April 2026). Source
  103. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Childhood Leukemia (Ages 0-19). Page accessed 20 October 2026; the page displays no update date (its HTML metadata gives 22 April 2026). Source
  104. Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics. J Clin Oncol. 2026;44(5):370-374. PubMedDOI
    CiteLoading…